Discovery of the First Selective Nanomolar Inhibitors of ERAP2 by Kinetic Target‐Guided Synthesis. (19th August 2022)

• Record Type: Journal Article
• Authors: Camberlein, Virgyl; Fléau, Charlotte; Sierocki, Pierre; Li, Lenong; Gealageas, Ronan; Bosc, Damien; Guillaume, Valentin; Warenghem, Sandrine; Leroux, Florence; Rosell, Melissa; Cheng, Keguang; Medve, Laura; Prigent, Mathilde; Decanter, Myriam; Piveteau, Catherine; Biela, Alexandre; Eveque, Maxime; Dumont, Julie; Mpakali, Anastasia; Giastas, Petros; Herledan, Adrien; Couturier, Cyril; Haupenthal, Jörg; Lesire, Laetitia; Hirsch, Anna K. H.; Deprez, Benoit; Stratikos, Efstratios; Bouvier, Marlene; Deprez‐Poulain, Rebecca
• Is Part Of: Angewandte Chemie. Volume 134:Number 39(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-19
• Subjects: ERAP2 -- Isoform Selectivity -- Medicinal Chemistry -- Metalloenzymes -- Protein-Templated Reactions; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.202203560
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a key enzyme involved in the trimming of antigenic peptides presented by Major Histocompatibility Complex class I. It is a target of growing interest for the treatment of autoimmune diseases and in cancer immunotherapy. However, the discovery of potent and selective ERAP2 inhibitors is highly challenging. Herein, we have used kinetic target‐guided synthesis (KTGS) to identify such inhibitors. Co‐crystallization experiments revealed the binding mode of three different inhibitors with increasing potency and selectivity over related enzymes. Selected analogues engage ERAP2 in cells and inhibit antigen presentation in a cellular context. 4 d (BDM88951 ) displays favorable in vitro ADME properties and in vivo exposure. In summary, KTGS allowed the discovery of the first nanomolar and selective highly promising ERAP2 inhibitors that pave the way of the exploration of the biological roles of this enzyme and provide lead compounds for drug discovery efforts. Abstract : Kinetic target‐guided synthesis and optimisation led to the first nanomolar ERAP2 inhibitors with outstanding selectivity. The binding modes of the most potent inhibitors were elucidated by X‐ray crystallography. Our frontrunners engage target in cells and display good in vitro and in vivo pharmacokinetic properties.